SCYNEXIS公司已启动其新型AMPK激活剂Scy-770的I期临床研究,该药物旨在用于治疗常染色体显性多囊肾病(ADPKD)。这项研究标志着该候选药物在开发进程中的关键一步。
SCYNEXIS公司已启动其新型AMPK激活剂Scy-770的I期临床研究,该药物旨在用于治疗常染色体显性多囊肾病(ADPKD)。这项研究标志着该候选药物在开发进程中的关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.